Related Experiment Video

Updated: Jun 9, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.5K

Advances in the Development of Antiviral Compounds for Rotavirus Infections

María Julieta Tohmé1,2, Laura Ruth Delgui3,4

  • 1IHEM, Universidad Nacional de Cuyo, CONICET, Facultad de Ciencias Médicas, Mendoza, Argentina.

Mbio
|May 12, 2021
PubMed

Insights

Group A rotaviruses (RVAs) cause severe gastroenteritis in children globally. This review explores novel antiviral strategies targeting RVA structure and replication for potential treatments.

Area of Science:

  • Virology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Group A rotaviruses (RVAs) are a leading cause of severe acute gastroenteritis (AGE) in children under five, responsible for significant global mortality.
  • Challenges in managing RVA infections include socio-economic factors affecting treatment access and vaccine effectiveness, alongside a lack of specific antiviral drugs.
  • RVAs pose a persistent global health concern due to their widespread impact on young children.

Purpose of the Study:

  • To provide an updated overview of antiviral compounds for Group A rotavirus (RVA) infections.
  • To correlate recent advancements in RVA virion structure and replication with potential therapeutic strategies.
  • To explore novel, broad-spectrum therapeutic options for RVA-associated AGE.

Main Methods:

  • Review of current literature on RVA virion structure and replication mechanisms.
  • Analysis of emerging antiviral compounds and therapeutic approaches.
  • Identification and evaluation of potential drug targets, including host factors and conserved viral proteins.

Main Results:

  • The review highlights the significance of RVA virion structure and replication cycle in identifying therapeutic targets.
  • Novel strategies focus on modulating host factors, lipid droplets, and the highly conserved viral polymerase.
  • These approaches offer potential for broad-spectrum antiviral activity against AGE-causing viruses.

Conclusions:

  • Understanding RVA structure and replication is crucial for developing effective antiviral treatments.
  • Targeting host factors and conserved viral components like the polymerase presents promising avenues for novel therapies.
  • Further research into these targets could lead to broad-spectrum treatments for RVA-associated gastroenteritis.

Keywords:
antivirallipid dropletsrotavirus

More Related Videos

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus10:49

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus

Published on: January 28, 2019

9.0K
Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins11:40

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins

Published on: April 17, 2020

9.0K

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...